Tagrisso significantly improves progression-free survival in the Phase III FLAURA trial for lung cancer

Click here to view online. Add this email to your safelist.

27 July 2017

Tagrisso met the primary endpoint, demonstrating a statistically-significant and clinically-meaningful progression-free survival benefit in 1st-line EGFRm non-small cell lung cancer compared to current standard-of-care treatment

RSS Feed

Legal notice and Terms of Use

Cookie policy

Site map

For more information please visit astrazeneca.com.

If you would like to unsubscribe please click here.